XAI for Drug Discovery

2023

Closed access Metadata (CSL-JSON)
DOI 10.1201/9781032629353-13
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Since the improvement of a new drug is a complex, costly, and a quite overlong process, how to decrease prices and speed up new drug discovery has turned into a compelling and immediate problem in the industry. So, the importance of computer-aided drug discovery has been steadily increasing in recent times. Notwithstanding the increasing number of accomplished forward-looking practices, deep learning models need to be explainable as mathematical models are often difficult to interpret by the human mind. In this study, first, basic information about current explainable artificial intelligence (XAI) methods such as class activation mapping (CAM), local interpretable model-agnostic explanations (LIME), SHAP, Fairlearn, and Whitenoise is given. Afterward, XAI approaches used in the context of drug discovery such as feature attribution, instance-based, graph-convolution based, self- explaining, and uncertainty prediction are mentioned and predictions for future studies are made.